Holdings
Affinity Asset Advisors, LLC
As of Sep 30, 2026, Affinity Asset Advisors, LLC reported 97 positions worth US$1.6B. Largest: Roivant Sciences Ltd., Spyre Therapeutics, Inc. and Erasca, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 3.2M | US$117M | −550K | Sep 30, 2026 |
| Spyre Therapeutics, Inc. | 1.28M | US$114M | no change | Sep 30, 2026 |
| Erasca, Inc. | 5.59M | US$82M | +341K | Sep 30, 2026 |
| First Tracks Biotherapeutics, Inc. | 2.08M | US$73.7M | +47,988 | Sep 30, 2026 |
| Xenon Pharmaceuticals Inc. | 1.9M | US$70.7M | +305K | Sep 30, 2026 |
| Insmed Incorporated | 564K | US$64.4M | −85,749 | Sep 30, 2026 |
| Oruka Therapeutics, Inc. | 600K | US$50M | +10,000 | Sep 30, 2026 |
| Avalo Therapeutics, Inc. | 3.24M | US$49.7M | +345K | Sep 30, 2026 |
| Cytokinetics, Incorporated | 750K | US$49.4M | +200K | Sep 30, 2026 |
| Revolution Medicines, Inc. | 225K | US$46.2M | −25,000 | Sep 30, 2026 |